Drug Therapy for Atrial Fibrillation

Medical Clinics of North America

Volumn 92, Issue 1, 2008, Pages 121-141

  Musco, Simone ^a   Conway, Emily L ^a   Kowey, Peter R ^a,b  

^a Main Line Heart Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; ATI 2001; ATI 2042; AZIMILIDE; BENZOFURAN DERIVATIVE; BERTOSAMIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELIVARONE; DIGOXIN; DILTIAZEM; DOFETILIDE; DRONEDARONE; ESMOLOL; FLECAINIDE; IBUTILIDE; METOPROLOL; PLACEBO; PROPAFENONE; PROPRANOLOL DERIVATIVE; RSD 1235; SOTALOL; SSR 149744C; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VERNAKALANT; WARFARIN;

ATRIOVENTRICULAR CONDUCTION; BLEEDING; BRADYCARDIA; BRONCHOSPASM; CARDIOVERSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EYE TOXICITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LIVER TOXICITY; LUNG DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OPTIC NERVE DISEASE; PATIENT CARE; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SINUS RHYTHM; SKIN DISCOLORATION; SUSTAINED RELEASE FORMULATION; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEART RATE; HUMANS; TREATMENT OUTCOME;

EID: 36448992291     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.08.002     Document Type: Review

References (100)

1. Go A., Hylek E., Phillips K., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation study. JAMA 285 (2001) 2370-2375
2. Wyse D.G., Waldo J.P., DiMarco J.M., et al., The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
3. Van Gelder I., Hagens V., Bosker H., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
4. Chung M.K., Shemanski L., Sherman D.G., et al. Functional status in rate-versus rhythm control strategies for atrial fibrillation. J Am Coll Cardiol 46 (2005) 1891-1899
5. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 48 4 (2006) e149-e246
6. Naccarelli G.V., Wolbrette D.L., Bhatta L., et al. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J Interv Card Electrophysiol 9 (2003) 215-222
7. Nattel S., and Lionel H.O. Controversies in atrial fibrillation. Lancet 367 (2006) 262-272
8. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation. Arch Intern Med 166 (2006) 719-728
9. Naccarelli G.V., Wolbrette D.L., Khan M., et al. Old and new antiarrhythmic drugs for converting and maintaining siuns rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 91 Suppl (2003) 15D-26D
10. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342 (2000) 913-920
11. Singh B.N., Singh S.N., Reda D.J., et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005) 1861-1872
12. Deedwania P.C., Singh B.N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation 98 (1998) 2574-2579
13. Chimenti M., Cullen M.T., and Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 77 3 (1996) 60A-75A
14. Meinertz T., Lip G.Y., Lombardi F., et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 90 12 (2002) 1300-1306
15. Pritchett E.L.C., Page R.L., Carlson M., et al. Efficacy and safety of sustained-release propafenone (Propafenone SR) for patients with atrial fibrillation. Am J Cardiol 92 (2003) 941-946
16. Torp-Pederson C., Mooler M., Block-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341 (1999) 857-865
17. Pedersen O.D., Bagger H., Keller N., et al. Efficacy of Dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. Circulation 104 (2001) 292-296
18. Singh S., Zoble R.G., Yellen L., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. Circulation 102 (2000) 2385-2390
19. Greenbaum R.A., Campbell T.J., Channer K.S., et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study. [abstract]. Circulation 98 (1998) 1633
20. Alboni P., Botto G.L., Baldi N., et al. Outpatient treatment of recent-onset atrial fibrillation with the "Pill-in-the-Pocket" approach. N Engl J Med 351 (2004) 2384-2391
21. Boriani G., Diemberger I., Biffi M., et al. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 64 24 (2004) 2741-2762
22. Reiffel J.A. Maintenance of normal sinus rhythm with antiarrhythmic drugs. In: Kowey P., and Naccarelli G. (Eds). Atrial fibrillation (2005), Marcel Dekker, New York 195-217
23. Goldstein R.N., and Stambler B.S. New antiarrhythmic drugs for prevention of atrial fibrillation. Prog Cardiovasc Dis 48 3 (2005) 193-208
24. Pecini R., Elming H., Pedersen O.D., et al. New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs 10 2 (2005) 311-322
25. Sun W., Sarma J.S., and Singh B.N. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 100 22 (1999) 2276-2281
26. Sun W., Sarma J.S., and Singh B.N. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 39 5 (2002) 677-684
27. Touboul P., Brugada J., Capucci A., et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24 16 (2003) 1481-1487
28. Hohnloser SH. EURIDIS and ADONIS: maintenance of sinus rhythm with dronedarone in patients with atrial fibrillation or flutter. Hot Line II: acute coronary syndromes/medical treatment II. Presented at the European Society of Cardiology Congress 2004. Munich (Germany), August 28-September 1, 2004.
29. Davy JM, on behalf of the ERATO Investigators. Dronedarone demonstrates additional rate control on top of standard pharmacotherapies in the treatment of atrial fibrillation. American Heart Association, Scientific sessions 2005, session number APS.52.4, presentation 2737.
30. Sanofi-Aventis. Discontinuation of one of the studies (ANDROMEDA) with dronedarone. 17 January 2003. Press release.
31. Available at: http://www.clinicaltrials.gov Trial identifier NCT00174785.
32. Gautier P., Guillemare E., Djandjighian L., et al. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol 44 2 (2004) 244-257
33. Available at: http://www.clinicaltrials.gov. Trial identifier NCT00233441.
34. Available at: http://www.clinicaltrials.gov. Trial identifier NCT00232310.
35. Raatikainen M.J., Napolitano C.A., Druzgala P., et al. Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart. J Pharmacol Exp Ther 277 3 (1996) 1454-1463
36. Raatikainen M.J., Morey T.E., Druzgala P., et al. Potent and reversible effects of ATI-2001 on atrial and atrioventricular nodal electrophysiological properties in guinea pig isolated perfused heart. J Pharmacol Exp Ther 295 2 (2000) 779-785
37. Juhasz A., and Bodor N. Cardiovascular studies on different classes of soft drugs. Pharmazie 55 3 (2000) 228-238
38. Morey T.E., Seubert C.N., Raatikainen M.J., et al. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther 297 1 (2001) 260-266
39. Salata J.J., and Brooks R. Pharmacology of Azimilide Dihydrochloride (NE-10064). Cardiovasc Drug Rev 15 (1997) 137-156
40. Pritchett E.L., Page R.L., Connolly S.J., et al. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J Am Coll Cardiol 36 3 (2000) 794-802
41. Camm A.J., Pratt C.M., Schwartz P.J., et al. AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109 8 (2004) 990-996
42. Page R.L. A-STAR and A-COMET trials (Azimilide in atrial fibrillation). [abstract]. Europace 3 (2002) A-2
43. Pritchett E.L., Kowey P., Connolly S., et al. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J 151 5 (2006) 1043-1049
44. Lombardi F., Borggrefe M., Ruzyllo W., et al. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J 27 18 (2006) 2224-2231
45. Kerr C.R., Connolly S.J., Kowey P., et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol 98 2 (2006) 215-218
46. Connolly S.J., Schnell D.J., Page R.L., et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 88 (2001) 974-979
47. Ravens U., Amos G.J., Li Q., et al. Effects of the antiarrhythmic agent tedisamil. Exp Clin Cardiol 2 (1997) 231-236
48. Hohnloser S.H., Dorian P., Straub M., et al. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 44 1 (2004) 99-104
49. Beatch G.N., Shinagawa K., Johnson B., et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. [abstract]. Pacing Clin Electrophysiol 25 (2002) 698
50. Beatch G.N., Lin S.-P., Hesketh J.C., et al. Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug. [abstract]. Circulation 108 (2003) IV85
51. Ezrin A.M., Grant S.M., Bell G., et al. A dose-ranging study of RSD1235, a novel antiarrhythmic agent, in healthy volunteers. [abstract]. Pharmacologist 44 Suppl 1 (2002) A15
52. Roy D., Rowe B.H., Stiell I.G., et al., CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 44 12 (2004) 2355-2361
53. Available at: http://www.cardiome.com/RSD1235Intravenous.php.
54. Available at: http://www.cardiome.com/VernakalantIntravenous.php.
55. Available at: http://www.clinicaltrials.gov Trial identifier: NCT00267930.
56. Available at: http://www.clinicaltrials.gov Trial identifier: NCT00125320.
57. Wirth K.J., Paehler T., Rosenstein B., et al. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc Res 60 2 (2003) 298-306
58. Blaauw Y., Gogelein H., Tieleman R.G., et al. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110 13 (2004) 1717-1724
59. Goldstein R.N., Khrestian C., Carlsson L., et al. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 15 12 (2004) 1444-1450
60. Wu Y., Carlsson L., Liu T., et al. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol 16 8 (2005) 898-904
61. Available at: http://www.clinicaltrials.gov. Trial identifier: NCT00255281.
62. Kaumann A.J., Sanders L., Brown A.M., et al. A 5-HT receptor in human atrium. Br J Pharmacol 100 (1990) 879-885
63. Grammer J.B., Zeng X., Bosch R.F., et al. Atrial L-type Ca2+-channel, beta-adrenorecptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res Cardiol 96 1 (2001) 82-90
64. Rahme M.M., Cotter B., Leistad E., et al. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation 100 19 (1999) 2010-2017
65. Xiao X.D., Fuchs S., Campbell D.J., et al. Mice with cardiac-restricted ACE have atrial enlargement, cardiac arrhythmias and sudden death. Am J Pathol 165 (2004) 1019-1032
66. Boss C.J., and Lip G.Y. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 19 (2005) 855-859
67. Shi Y., Tardif J.C., and Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 54 (2002) 456-461
68. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 4 (1999) 376-380
69. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107 23 (2003) 2926-2931
70. L'Allier P.L., Ducharme A., Keller P.F., et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 44 1 (2004) 159-164
71. Anand K., Mooss A.N., Hee T.T., et al. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 152 2 (2006) 217-222
72. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
73. Ueng K.C., Tsai T.P., Yu W.C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 24 23 (2003) 2090-2098
74. Available at: http://www.clinicaltrials.gov/ct/show/NCT00141778?order=1.
75. Nakashima H., Kumagai K., Urata H., et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101 22 (2000) 2612-2617
76. Kumagai K., Nakashima H., Urata H., et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41 12 (2003) 2197-2204
77. Maggioni A.P., Latini R., Carson P.E., et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 3 (2005) 548-557
78. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 5 (2005) 712-719
79. Fogari R., Mugellini A., Destro M., et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 47 1 (2006) 46-50
80. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 3 (2002) 331-336
81. Tveit A., Grundvold I., Olufsen M., et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 120 1 (2007) 85-91
82. Available at: http://www.clinicaltrials.gov/ct/show/NCT00098137?order=1.
83. Disertori M., Latini R., Maggioni A.P., et al. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown) 7 1 (2006) 29-38
84. Caballero R., Moreno I., Gonzalez T., et al. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 107 6 (2003) 889-895
85. Gomez R., Nunez L., Caballero R., et al. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels. Br J Pharmacol 146 1 (2005) 146-161
86. Goldstein R.N., Kyungmoo R., Van Wagoner D.R., et al. Prevention of postoperative atrial fibrillation and flutter using steroids. [abstract]. Pacing Clin Electrophysiol 26 (2003) 1068
87. Halonen J., Halonen P., Jarvinen O., et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery. JAMA 297 (2007) 1562-1567
88. Prasongsukarn K., Abel J.G., Jamieson W.R., et al. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial. J Thorac Cardiovasc Surg 130 1 (2005) 93-98
89. Halvorsen P., Raeder J., White P.F., et al. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg 96 6 (2003) 1578-1583
90. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 1 (2004) 105-111
91. Shiroshita-Takeshita A., Schram G., Lavoie J., et al. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 16 (2004) 2313-2319
92. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 11 (2003) 1343-1345
93. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 12 (2003) 1379-1383
94. Amar D., Zhang H., Heerdt P.M., et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 128 5 (2005) 3421-3427
95. Marin F., Pascual D.A., Roldan V., et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97 1 (2006) 55-60
96. Available at: http://www.clinicaltrials.gov/ct/show/NCT00252967?order=1.
97. Ninio D.M., Murphy K.J., Howe P.R., et al. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol 16 11 (2005) 1189-1194
98. Biscione F., Totteri A., De Vita A., et al. Effect of omega-3 fatty acids on the prevention of atrial arrhythmias. Ital Heart J 6 1 (2005) 53-59
99. Calo L., Bianconi L., Colivicchi F., et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 45 10 (2005) 1723-1728
100. Brouwer I.A., Heeringa J., Geleijnse J.M., et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 151 4 (2006) 857-862